Cargando…

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability...

Descripción completa

Detalles Bibliográficos
Autores principales: Melichar, Bohuslav, Hyšpler, Radomír, Dragounová, Emanuela, Dvořák, Josef, Kalábová, Hana, Tichá, Alena
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1973082/
https://www.ncbi.nlm.nih.gov/pubmed/17688683
http://dx.doi.org/10.1186/1471-2407-7-155
_version_ 1782135035529265152
author Melichar, Bohuslav
Hyšpler, Radomír
Dragounová, Emanuela
Dvořák, Josef
Kalábová, Hana
Tichá, Alena
author_facet Melichar, Bohuslav
Hyšpler, Radomír
Dragounová, Emanuela
Dvořák, Josef
Kalábová, Hana
Tichá, Alena
author_sort Melichar, Bohuslav
collection PubMed
description BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity.
format Text
id pubmed-1973082
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19730822007-09-08 Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum Melichar, Bohuslav Hyšpler, Radomír Dragounová, Emanuela Dvořák, Josef Kalábová, Hana Tichá, Alena BMC Cancer Research Article BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability represents one of the potential methods of noninvasive laboratory assessment of gastrointestinal mucositis induced by chemotherapy, but little is known about intestinal permeability in patients treated with paclitaxel or platinum. METHODS: Intestinal permeability was assessed in 36 breast and ovarian cancer patients treated with paclitaxel/platinum combination by measuring, using capillary gas chromatography, urinary sucrose, lactulose, xylose and mannitol after oral challenge. The significance of differences during the therapy compared to pre-treatment values was studied by Wilcoxon paired test. The differences between groups of patient were studied by Mann-Whitney U test. Fisher exact test was used to compare the frequency in different subgroups. RESULTS: After administration of the first dose, a significant (p < 0.05) decrease in xylose absorption and increased lactulose/mannitol, sucrose/mannitol, lactulose/xylose and sucrose/xylose ratios were observed, but these parameters returned subsequently to pre-treatment levels. Patients who experienced serious (grade 3 or 4) toxicity had at baseline significantly lower percentages of xylose, mannitol and sucrose, and higher lactulose/mannitol ratio. Nine of 13 (69%) patients with baseline lactulose/mannitol ratio 0.070 or above experienced serious toxicity compared to 4 out of 23 patients (17%) with the ratio below 0.070 (p = 0.002). Post-treatment lactulose, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were significantly increased in patients with serious toxicity. CONCLUSION: A transient significant increase in lactulose/monosaccharide and sucrose/monosaccharide ratios was observed in ovarian and breast cancer patients treated with paclitaxel and platinum. Increased lactulose absorption, lactulose/mannitol, sucrose/mannitol and lactulose/xylose ratios were evident in patients with grade 3 or 4 toxicity, and increased baseline lactulose/mannitol ratio predicted serious toxicity. BioMed Central 2007-08-09 /pmc/articles/PMC1973082/ /pubmed/17688683 http://dx.doi.org/10.1186/1471-2407-7-155 Text en Copyright © 2007 Melichar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Melichar, Bohuslav
Hyšpler, Radomír
Dragounová, Emanuela
Dvořák, Josef
Kalábová, Hana
Tichá, Alena
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title_full Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title_fullStr Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title_full_unstemmed Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title_short Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
title_sort gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1973082/
https://www.ncbi.nlm.nih.gov/pubmed/17688683
http://dx.doi.org/10.1186/1471-2407-7-155
work_keys_str_mv AT melicharbohuslav gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum
AT hysplerradomir gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum
AT dragounovaemanuela gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum
AT dvorakjosef gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum
AT kalabovahana gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum
AT tichaalena gastrointestinalpermeabilityinovariancancerandbreastcancerpatientstreatedwithpaclitaxelandplatinum